Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp47291_8k.htm |
EXHIBIT 99.1
|
Press Release
|
 |
|
www.shire.com
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Shire Update Call for Investors
Dublin, Ireland – June 20, 2014 – Shire plc (“Shire” or the “Company”) (LSE: SHP, NASDAQ: SHPG) announces that, following today’s earlier announcement concerning the Board of Shire’s rejection of AbbVie Inc’s unsolicited and highly conditional proposal regarding the possible cash and share offer for the Company, Shire intends to host an investor call with management on Monday June 23, 2014 at 1pm BST / 8am EDT.
The details of the conference call are as follows:
|
UK dial in:
|
08082370030 or 02031394830
|
|
US dial in:
|
1866 928 7517 or 1 718 873 9077
|
|
International Access Numbers:
|
http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_List.pdf
|
|
Password/Conf ID:
|
40849384#
|
|
Live Webcast:
|
http://www.shire.com/shireplc/en/investors
|
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for three months. Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.
For further information please contact:
|
Investor Relations
|
||
|
Jeff Poulton
|
jpoulton@shire.com
|
+1 781 482 0945
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
|
Media
|
||
|
Jessica Mann
|
jmann@shire.com
|
+44 1256 894 280
|
|
Stephanie Fagan
|
sfagan@shire.com
|
+1 781 482 0460
|
ACCESS TO CALL AND PRESENTATION
The investor call and the presentation are not directed at, or to be accessed or attended by, persons located or resident in any jurisdiction where the relevant action would constitute a violation of the relevant laws and regulations of such jurisdiction or would result in a requirement to comply with any governmental or other consent or any registration, filing or other formality which Shire regards as unduly onerous. All persons resident or located outside the United Kingdom or the United States who wish to attend or access the call or materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and should inform themselves of, and observe, any applicable legal or regulatory requirements applicable in their jurisdiction. Shire and its advisers do not assume any responsibility for any violation by any person of any of these restrictions.
The information provided during the call and in the presentation is being made available in good faith and for information purposes only and does not constitute an offer to sell or otherwise dispose of or an invitation or solicitation of any offer to purchase or subscribe for any securities or otherwise in any jurisdiction in which such offer or solicitation is unlawful.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
www.shire.com